These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 7812982)

  • 41. Zinc in human malignancies.
    Chakravarty PK; Ghosh A; Chowdhury JR
    Neoplasma; 1986; 33(1):85-90. PubMed ID: 3960212
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Measurement of human serum immunoreactive gamma-glutamyl transpeptidase in patients with malignant tumors using enzyme-linked immunosorbent assay.
    Taniguchi N; Iizuka S; Zhe ZN; House S; Yokosawa N; Ono M; Kinoshita K; Makita A; Sekiya C
    Cancer Res; 1985 Nov; 45(11 Pt 2):5835-9. PubMed ID: 2865006
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Concentration of neuraminic acid in the serum of tumor patients (author's transl)].
    Prignitz R; Rainer K; Biller H; Prignitz I
    Strahlentherapie; 1981 Jan; 157(1):37-40. PubMed ID: 7210046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Quantitative immunoenzyme determination of the lactoferrin and alpha-lactalbumin in the blood serum of cancer patients].
    Vasil'ev MIu; Avdeev GI
    Eksp Onkol; 1985; 7(5):56-60. PubMed ID: 4065022
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of a radioimmunoassay for alpha 1-acid glycoprotein to monitor therapy of cancer patients.
    Ganz PA; Shell WE; Tökés ZA
    J Natl Cancer Inst; 1983 Jul; 71(1):25-30. PubMed ID: 6575206
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical significance of serum ferritin levels in malignant tumors treated by radiotherapy].
    Mitsuhashi N; Okazaki A; Hayakawa K; Nakano T; Yamanaka M; Itoh J; Hiraoka S; Aoki N; Niibe H
    Nihon Gan Chiryo Gakkai Shi; 1983 Oct; 18(7):1798-805. PubMed ID: 6672133
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.
    Wu Y; Han B; Sheng H; Lin M; Moore PA; Zhang J; Wu J
    Int J Cancer; 2003 Jul; 105(5):724-32. PubMed ID: 12740925
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of fucose level in glycoprotein fraction of serum in patients with malignant tumors.
    Tatsumura T; Sato H; Mori A; Komori Y; Yamamoto K; Fukatani G; Kuno S
    Cancer Res; 1977 Nov; 37(11):4101-3. PubMed ID: 908042
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beta-1 integrins in renal cell carcinoma--an immunohistochemical study.
    Heicappell R; Podlinski J; Mückshoff U; Buszello H; Ackermann R
    Investig Urol (Berl); 1994; 5():42-50. PubMed ID: 7719319
    [No Abstract]   [Full Text] [Related]  

  • 50. [Somatomedin activity in patients with malignant neoplasms].
    Vasil'eva IA; Dil'man VM
    Vopr Onkol; 1988; 34(5):531-4. PubMed ID: 2837869
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzyme-linked-immunosorbent-assay for the detection of a novel 21-kda protein associated with the clinical course of patients with urogenital tumors.
    Shalitin C; Epelbaum R; Moskovitz B; Segal R; Valansi C; Mekori T; Lerner M
    Int J Oncol; 1992 Jun; 1(1):107-12. PubMed ID: 21584517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [On the occurrence of additionally limitable gamma globulin fractions in agar gel electrophoresis in patients with neoplastic diseases].
    Lohmann D; Zimmermann S; Gläser A
    Dtsch Med Wochenschr; 1969 Jan; 94(5):213-7. PubMed ID: 4178490
    [No Abstract]   [Full Text] [Related]  

  • 53. A novel 21-kDa protein as a serum marker for benign and malignant urogenital tumors: preliminary communication.
    Shalitin C; Epelbaum R; Valansi C; Segal R; Mekori T; Lover B; Robinson E
    Int J Cancer; 1991 Dec; 49(6):861-6. PubMed ID: 1959989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Immunochemical investigations on serum proteins of tumor patients (author's transl)].
    Rimbaut C; Tilz GP; Buffe D
    Med Klin; 1974 Aug; 69(35):1399-1401. PubMed ID: 4425176
    [No Abstract]   [Full Text] [Related]  

  • 55. [Determination of urinary immunosuppressive acidic protein in cancer patients].
    Hirayama T; Tamura K; Kikuchi S; Shibata Y; Kanno H; Sato Y; Ishida N; Kikuchi K
    Gan No Rinsho; 1983 Sep; 29(11):1323-9. PubMed ID: 6685196
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Radioimmunologic analysis of changes in the level of beta-2-microglobulin in cancer].
    Zubovskiĭ LG; Polevaia EB; Kirsanov AG; Shiriaev SV
    Med Radiol (Mosk); 1982 Aug; 27(8):50-3. PubMed ID: 6182439
    [No Abstract]   [Full Text] [Related]  

  • 57. [Histamine levels in the blood in patients with malignant tumors].
    Sabolović D; Dubravcić D; Culo F; Hadzić N
    Lijec Vjesn; 1989; 111(6-7):185-7. PubMed ID: 2796570
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The levels of NAD and NADH in blood of patients with cancer.
    Comes R; Mustea I
    Neoplasma; 1976; 23(4):451-5. PubMed ID: 187970
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Alpha 1-antitrypsin as a tumor marker].
    Schena M; Quadri A; Ragazzoni G; Corti P
    Quad Sclavo Diagn; 1985 Mar; 21(1):87-96. PubMed ID: 3877314
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasmatic fibronectin in malignancies.
    Gallurt P; Rodriguez P; Lorenzo A; López Saez JJ; Senra A; Millán J
    Int J Biol Markers; 1992; 7(4):240-3. PubMed ID: 1491180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.